CONTEXT: The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy. OBJECTIVES: In this cross-sectional study, we evaluated for associations between perceived stress and the occurrence of CIPN, hearing loss, and tinnitus, in 623 adult cancer survivors who received platinum and/or taxane compounds. METHODS: Survivors completed self-report measures of hearing loss, tinnitus, and perceived stress (i.e., Impact of Events Scale-Revised [IES-R]). Separate logistic regression analyses were done for each neurotoxicity to evaluate whether each of the IES-R subscale (i.e., intrusion, avoidance, hyperarousal) and total scores made a significant independent contribution to neurotoxicity group membership. RESULTS: Of the 623 survivors in this study, 68.4% had CIPN, 34.5% reported hearing loss, and 31.0% reported tinnitus. Older age, higher body mass index, poorer functional status, being born prematurely, cancer diagnosis, and higher intrusion (P = 0.013), hyperarousal (P = 0.014), and total (P = 0.047) IES-R scores were associated with CIPN. Older age, being male, poorer functional status, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.007) score were associated with hearing loss. Being male, having less education, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.029) score were associated with tinnitus. CONCLUSION: These findings suggest that increased levels of perceived stress are associated with the most common chemotherapy-induced neurotoxicities.
CONTEXT: The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy. OBJECTIVES: In this cross-sectional study, we evaluated for associations between perceived stress and the occurrence of CIPN, hearing loss, and tinnitus, in 623 adult cancer survivors who received platinum and/or taxane compounds. METHODS: Survivors completed self-report measures of hearing loss, tinnitus, and perceived stress (i.e., Impact of Events Scale-Revised [IES-R]). Separate logistic regression analyses were done for each neurotoxicity to evaluate whether each of the IES-R subscale (i.e., intrusion, avoidance, hyperarousal) and total scores made a significant independent contribution to neurotoxicity group membership. RESULTS: Of the 623 survivors in this study, 68.4% had CIPN, 34.5% reported hearing loss, and 31.0% reported tinnitus. Older age, higher body mass index, poorer functional status, being born prematurely, cancer diagnosis, and higher intrusion (P = 0.013), hyperarousal (P = 0.014), and total (P = 0.047) IES-R scores were associated with CIPN. Older age, being male, poorer functional status, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.007) score were associated with hearing loss. Being male, having less education, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.029) score were associated with tinnitus. CONCLUSION: These findings suggest that increased levels of perceived stress are associated with the most common chemotherapy-induced neurotoxicities.
Authors: Mark P Jensen; Arnold R Gammaitoni; David O Olaleye; Napoleon Oleka; Srinivas R Nalamachu; Bradley S Galer Journal: J Pain Date: 2006-11 Impact factor: 5.820
Authors: Daniel L Hall; Inga T Lennes; William F Pirl; Emily R Friedman; Elyse R Park Journal: Support Care Cancer Date: 2016-12-13 Impact factor: 3.603
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Omar El Charif; Brandon Mapes; Matthew R Trendowski; Heather E Wheeler; Claudia Wing; Paul C Dinh; Robert D Frisina; Darren R Feldman; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Eric R Gamazon; Nancy J Cox; Robert Huddart; Shirin Ardeshir-Rouhani-Fard; Patrick Monahan; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2019-04-05 Impact factor: 12.531
Authors: Tara Stacker; Kord M Kober; Laura Dunn; Carol Viele; Steven M Paul; Marilyn Hammer; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022-03-02 Impact factor: 2.760
Authors: Larissa Staurengo-Ferrari; Ivan J M Bonet; Dioneia Araldi; Paul G Green; Jon D Levine Journal: J Neurosci Date: 2021-12-08 Impact factor: 6.709
Authors: Melissa Mazor; Steven M Paul; Margaret A Chesney; Lee-May Chen; Betty Smoot; Kimberly Topp; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Date: 2019-09-10 Impact factor: 6.860
Authors: Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2018-10-10 Impact factor: 12.531
Authors: Shirin ArdeshirRouhaniFard; Paul C Dinh; Patrick O Monahan; Sophie D Fossa; Robert Huddart; Chunkit Fung; Yiqing Song; Darren R Feldman; Robert J Hamilton; David J Vaughn; Neil E Martin; Christian Kollmannsberger; Lawrence Einhorn; Kurt Kroenke; Lois B Travis Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04-13 Impact factor: 4.254
Authors: Larissa Staurengo-Ferrari; Paul G Green; Dionéia Araldi; Luiz F Ferrari; Christine Miaskowski; Jon D Levine Journal: Pain Date: 2021-03-01 Impact factor: 7.926